Clenbuterol

Clenbuterol is a selective beta-2 adrenergic agonist with an unusually long duration of action. Its licensed use, in the countries that license it for humans at all, is as a bronchodilator for asthma; it is not approved for human use in the United States, and its largest legitimate market is veterinary, principally horses ^[36].

Its reputation is entirely about body composition. Beta-2 agonism raises energy expenditure and fat oxidation and drives lipolysis in adipocytes ^[31], and in animals the effect is dramatic enough to have been studied as a livestock growth promoter: clenbuterol shifts carcass composition toward lean tissue in cattle, pigs and rodents, which is why the term repartitioning agent attaches to it ^[32][33]. It has been described in the sports literature as a possible substitute for anabolic steroids on that basis ^[35].

The human evidence does not follow. Controlled human data on clenbuterol is mostly respiratory and cardiovascular pharmacology rather than fat loss ^[30], and the substantial human literature on it as a physique drug consists of adverse-event reports: a systematic review of case reports and series in athletes, a descriptive study of adverse events from misuse for weight loss and bodybuilding, individual reports of overdose causing supraventricular tachycardia and atrial fibrillation, of myocarditis, and of exercise-associated rhabdomyolysis ^{[14][26][27][28][29]}.

It is also a food-safety issue. Clenbuterol residues in meat have caused mass poisoning outbreaks, and contaminated meat is a documented route to a positive doping test ^[13][37].

Clenbuterol is the compound on this shelf where the human evidence is almost entirely about harm, and it should be read that way.

A systematic review of case reports and case series in athletes catalogued the pattern: tachycardia, palpitations, tremor, chest pain, arrhythmia and emergency presentations ^[14]. A descriptive study of adverse events specifically from misuse for weight loss and bodybuilding found the same ^[26]. Individual reports fill in the severity: acute overdose producing supraventricular tachycardia and atrial fibrillation ^[27], clenbuterol-induced myocarditis ^[28], and rhabdomyolysis in a user who exercised on it ^[29]. Hypokalaemia and marked tremor are predictable at the doses people use, and the long half-life means an excessive dose cannot be waited out quickly.

The cardiac risk has a specific mechanism rather than being a vague caution: beta-2 stimulation in cardiac tissue drives the tachycardia and arrhythmia directly, and clenbuterol additionally impairs hERG channel maturation ^[11], which is a recognised route to dangerous rhythm disturbance.

Two further exposures are worth knowing. Clenbuterol residues in meat have caused outbreaks of food poisoning, including a documented cluster in Portugal, and surveillance continues to find it in beef and liver in some countries ^[13][37]; this is also a real and accepted route to an inadvertent positive doping test. And it has been found sold as a dietary supplement, meaning exposure has occurred in people who did not knowingly take a beta-2 agonist ^[17]. It is banned in sport and is not approved for human use in the United States. This entry is educational and is not medical advice; no dosing guidance is given here.

As a long-acting beta-2 adrenergic agonist, clenbuterol shows the documented interaction pattern of its class: additive cardiovascular and adrenergic stimulation when combined with other sympathomimetics, and functional antagonism with beta-blockers, which can also provoke bronchospasm. Its hypokalemic effect can be potentiated by concomitant xanthine derivatives (theophylline), corticosteroids, and potassium-losing diuretics, and the resulting low potassium heightens the risk of arrhythmia, a concern amplified alongside cardiac glycosides such as digoxin. Beta-agonist labeling also cautions against use with MAOIs or tricyclic antidepressants, which can potentiate cardiovascular effects, and against other QT-prolonging drugs. This is research information, not medical advice.

Checking a whole stack? Run it through interactions + stacks.

Clenbuterol was developed as a bronchodilator and marketed for asthma under names including Spiropent, entering human use in several European and Latin American countries while never being approved for human use in the United States. Human pharmacology from that era characterised its cardiac, pulmonary and neuromuscular effects against placebo and against terbutaline ^[30].

Its second life began in agriculture. Work in the 1980s showed that beta-agonists modify body composition in livestock, shifting carcass weight toward lean tissue, and clenbuterol became the archetype of the repartitioning agent ^[32][33]. Use in food animals was subsequently banned across major jurisdictions, but residues in meat persisted as a public-health problem, producing mass poisoning outbreaks and continuing surveillance findings ^[13][37].

The third life is athletic. By the 1990s it was being discussed openly in the sports medicine literature as a possible substitute for anabolic steroids, and detection methods and doping-control literature developed alongside ^[35][15]. It remains prominent in veterinary medicine, principally in horses, where its long-term effects on performance have been examined more rigorously than in any human population ^[36][34].

Clenbuterol has a reputation as the cutting drug, the one taken in the last weeks before a photograph, and it is treated in that context as a comparatively minor addition to a stack because it is not a steroid. That framing is the problem. It is not androgenic, but the harms it does have are cardiac, they are documented in humans, and they are the reason the published human literature about physique use consists of case reports rather than trials ^[14][26].

The fat-loss claim itself is usually stated with a confidence the evidence does not support. The dramatic body-composition results everyone has heard about come from cattle, pigs, rodents and horses ^[32][33]; a controlled trial showing meaningful fat loss in healthy humans is not part of the record. Given that, the honest summary is that the effect in people is inferred from other species and from mechanism, and the risk in people is directly observed.

The least-known fact about it is the most awkward one for its reputation. In horses, where chronic administration has actually been studied, long-term clenbuterol reduced athletic performance ^[34]. It is also a recurring cause of inadvertent doping positives through contaminated meat, which is an accepted explanation in anti-doping proceedings rather than an excuse.